Sotio
| Industry | Biotechnology, Pharmaceutical |
|---|---|
| Founded | 2010 |
| Founder | Petr Kellner |
| Headquarters | , |
Key people | Radek Spisek, Ph.D., CEO |
| Revenue | 176,068,000 Czech koruna (2021) |
| −319,386,000 Czech koruna (2021) | |
| −344,344,000 Czech koruna (2021) | |
| Total assets | 6,689,850,000 Czech koruna (2021) |
Number of employees | 200 |
| Website | https://www.sotio.com/ |
SOTIO Biotech is a clinical-stage biotechnology company focused on research and development of next-generation cancer immunotherapies, with operations in Europe and North America. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), a proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.